Literature DB >> 24838009

Synthesis of polyglutamide-based metal-chelating polymers and their site-specific conjugation to trastuzumab for auger electron radioimmunotherapy.

Yijie Lu1, Ghislaine Ngo Ndjock Mbong, Peng Liu, Conrad Chan, Zhongli Cai, Dirk Weinrich, Amanda J Boyle, Raymond M Reilly, Mitchell A Winnik.   

Abstract

Three types of metal-chelating polymers (MCPs) with hydrazide end groups were synthesized. (1) The first set of polymers (the F-series) was synthesized with a furan end group, and all of the pendant groups along the chain carried only a diethylenetriaminepentaacetic acid (DTPA) metal-chelating functionality. The hydrazide was introduced via a Diels-Alder reaction between the furan and 3,3'-N-[ε-maleimidocaproic acid] hydrazide (EMCH). (2) The P-series polymers was designed to carry several copies of a nuclear-localization peptide sequence (NLS peptides, CGYGPKKKRKVGG, harboring the NLS from the simian virus 40 large T-antigen) in addition to the DTPA metal-chelating groups. (3) The third type of polymer (the P-Py series) was a variation of the P-series polymers but with the introduction of a small number of pyrene chromophores along the backbone to allow for UV measurement of the incorporation of the MCPs into trastuzumab (tmab). These hydrazide-terminated polymers were site-specifically conjugated to aldehyde groups generated by NaIO4 oxidation of the pendant glycan in the Fc domain of tmab. The immunoconjugates were radiolabeled with (111)In and analyzed by SE-HPLC to confirm the attachment of the polymer to the antibody. HER2 binding assays demonstrated that neither the MCPs nor the presence of the NLS peptides interfered with specific antigen recognition on SK-Br-3 cells, although nonspecific binding was increased by polymer conjugation. Our results suggest that MCPs can be site-specifically attached to antibodies via oxidized glycans in the Fc domain and labeled with (111)In to construct radioimmunoconjugates with preserved immunoreactivity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24838009     DOI: 10.1021/bm500174p

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  8 in total

1.  Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations.

Authors:  Brendon E Cook; Rosemery Membreno; Brian M Zeglis
Journal:  Bioconjug Chem       Date:  2018-07-18       Impact factor: 4.774

Review 2.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

Review 3.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

Review 4.  Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Authors:  Jin Su Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-01-26

5.  Functionalization of Cellulose Nanocrystals with PEG-Metal-Chelating Block Copolymers via Controlled Conjugation in Aqueous Media.

Authors:  Melinda Guo; Sohyoung Her; Rachel Keunen; Shengmiao Zhang; Christine Allen; Mitchell A Winnik
Journal:  ACS Omega       Date:  2016-07-18

6.  Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications.

Authors:  Funmilola Fisusi; Nailah Brandy; Jingbo Wu; Emmanuel O Akala
Journal:  J Nanosci Nanomed       Date:  2020-02-03

Review 7.  Nanostructures as Radionuclide Carriers in Auger Electron Therapy.

Authors:  Nasrin Abbasi Gharibkandi; Joanna Gierałtowska; Kamil Wawrowicz; Aleksander Bilewicz
Journal:  Materials (Basel)       Date:  2022-02-01       Impact factor: 3.623

8.  Synthesis of Disulfide-Bridging Trehalose Polymers for Antibody and Fab Conjugation Using a Bis-Sulfone ATRP Initiator.

Authors:  Neil L Forsythe; Heather D Maynard
Journal:  Polym Chem       Date:  2021-02-11       Impact factor: 5.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.